BL0175 not checked

Shanghai Best-Link Bioscience, LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive BL0175 Injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), and thereafter once on Day 1 of each subsequent 28-day treatment cycle (CnD1). Each treatment cycle is defined as 28 consecutive days. The total dose per administration is 500 mg, administered as bilateral gluteal intramuscular injections at 250 mg per buttock. Treatment will continue until disease…”In the company’s words, NCT07658183 on ClinicalTrials.gov
Tested for
Breast Cancer (Locally Advanced or Metastatic), Breast Cancer, Ovarian Cancer, Endometrial Cancer, Postmenopausal Women
Main trialPhase 2
“The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The main questions it aims to answer are: 1. Which dose level of BL0175 demonstrates the optimal ORR? 2. What is the recommended phase 3 dose (RP3D) based on efficacy and safety data across the tested dose levels?”In the company’s words, NCT07658183 on ClinicalTrials.gov

Other drugs for Breast Cancer (Locally Advanced or Metastatic)

All 397 drugs for Breast Cancer (Locally Advanced or Metastatic)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Oct 2027 A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
Phase 1Recruiting 20 Feb 2026 A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
Phase 1Not yet recruiting 8 May 2026 A Study of Single Dose of BL0175 in Postmenopausal Women
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BL0175

Following is part of Solo: you see every change to BL0175 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in